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Background: The ongoing EORTC 22042–26042 trial evaluates the efficacy of high-dose radiotherapy (RT) in
atypical/malignant meningioma. The results of the Dummy Run (DR) and prospective Individual Case Review (ICR)
were analyzed in this Quality Assurance (QA) study.
Material/methods: Institutions were requested to submit a protocol compliant treatment plan for the DR and ICR,
respectively. DR-plans (n=12) and ICR-plans (n=50) were uploaded to the Image-Guided Therapy QA Center of
Advanced Technology Consortium server (http://atc.wustl.edu/) and were assessed prospectively.
Results: Major deviations were observed in 25% (n=3) of DR-plans while no minor deviations were observed. Major
and minor deviations were observed in 22% (n=11) and 10% (n=5) of the ICR-plans, respectively. Eighteen% of ICRs
could not be analyzed prospectively, as a result of corrupted or late data submission. CTV to PTV margins were
respected in all cases. Deviations were negatively associated with the number of submitted cases per institution
(p=0.0013), with a cutoff of 5 patients per institutions. No association (p=0.12) was observed between DR and ICR
results, suggesting that DR’s results did not predict for an improved QA process in accrued brain tumor patients.
Conclusions: A substantial number of protocol deviations were observed in this prospective QA study. The number
of cases accrued per institution was a significant determinant for protocol deviation. These data suggest that
successful DR is not a guarantee for protocol compliance for accrued patients. Prospective ICRs should be
performed to prevent protocol deviations.
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The objective of the European Organization for the
Research and Treatment of Cancer (EORTC) 22042–26042
(NCT00626730) open study is to assess the impact of
high-dose radiotherapy (RT) on progression-free survival,
treatment tolerance and post-treatment global cognitive
functioning in patients with a diagnosis of either atypical
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reproduction in any medium, provided the or(WHO grade III) meningioma. The study flows and the
details of the protocol have been described elsewhere [1].
The goal of Quality Assurance (QA) in RT is to reduce
variabilities and uncertainties related to the different steps
of treatment planning and actual patient irradiation, inclu-
ding but not limited to patient positioning and precise dose
delivery to the target volume that may have an impact on
tumor control or on the normal tissue toxicity [2]. As such,
QA is of paramount importance when delivering high dose
radiation to the brain in the context of a clinical trial. We
report the results of the QA analysis of the first fully digital
and prospective Individual Case Review (ICR) conducted in
an international multicenter clinical trial for brain tumor.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Radiotherapy protocol, treatment planning and QA
requirements
Institutions were asked to perform a 1–3 mm planning
Computed Tomography (CT) scan. Post-operative Mag-
netic Resonance Imaging (MRI) was compulsory. Target
delineation was based on pre- and post-operative diagnostic
imaging. Gross Tumor Volume (GTV) was defined as the
visible tumor on fused images of Gadolinium-enhanced
T1-MRI and planning CT-scan, including thickened dural
trails and hyperostotic bone regions. The Clinical Target
Volume (CTV) 1 (Simpson grade 1–3) and CTV2
(Simpson grade 4–5) had to include the GTV, with a
margin of maximum 10 and 5 mm respectively, in
order to account for microscopic disease extensions
based on the preoperative tumor bed and peritumoral
edema on imaging and pathology report. For patients
with Simpson’s stage 1–3, who did not have residual
tumor in the postoperative imaging, CTV was defined
according to preoperative imaging and pathology report.
The Planned Treatment Volume (PTV) -1 and PTV2
were defined as CTV1 and CTV2 plus a margin between
1–5 mm depending on the institutional protocols and
treatment technique.
Three-Dimensional Conformal RT (3D-CRT) or
Intensity-Modulated RT (IMRT) was delivered, according
to discretion of the principal investigator. Nominal photon
energies between 4 and 20 MV were used in fractions of
2 Gy, once per day. Independent from the WHO grading
(i.e. II & III), 60 Gy to the PTV1 was delivered for all
patients and for those with Simpson’s Stage >3, this treat-
ment was followed with 10 Gy boost for PTV2 [1] The
prescription point and dose homogeneity for each PTV
was in accordance with ICRU 50/62 reports [3,4]. Lower
and upper limits of cumulative doses for PTV were
defined according to the dose received by the 95% (D95%)
and 2% (D2%) of the PTV. To minimize under-dosage to
the PTV, it was required that no less than 95% of the PTV
should receive less than 95% of the prescribed dose.
Organs at risk (OAR) were delineated according to
ICRU 62: brainstem, pituitary, cochlea, optic chiasm and
optic nerves [4]. Recommended upper limit for the near
maximum doses (D2%) were: 56 Gy for pituitary, 50 Gy
for cochlea, 60 Gy for optic pathway structures, 64 Gy and
54 Gy for the brainstem surface and center, respectively.The digital central QA platform
The Dummy Run (DR)- and ICR-plans for all patients
in this study were submitted to the Image-Guided
Therapy QA Center of Advanced Technology Consortium
(ITC-ATC) (http://atc.wustl.edu/). The following steps
were followed for each DR and ICR: submission of the
digital treatment planning data in appropriate format,fulfilling submission information form and sending an
e-mail to ITC-ATC to indicate the submission.
The DR and ICR
During the DR procedure, participating centers were
requested to submit a protocol compliant treatment plan
prior to trial activation. The EORTC QA level of comple-
xity of this study was 4 [2]. As such, ICR was performed
prospectively for each patient who had been accrued in the
trial. The treatment planning data of all patients had to be
reviewed per protocol within 5 days before the start of RT.
The following protocol compliant digital data of all patients
had to be submitted: planning images; structure contours;
RT plan file; absolute 3D dose distribution (for each phase
and sum of the treatment); color isodose images and
dose-volume histograms for the total dose plan in absolute
dose for target volumes and OAR.
Plan evaluation
Two reviewers evaluated the plans (MC, DCW). Deviation
parameters for tumor control and normal tissue toxicity are
detailed in Table 1. For each target and OAR, a qualitative
evaluation was made by inspection of the absorbed-dose
distributions slice-by-slice to make sure that the PTV was
adequately irradiated and OAR were adequately spared for
each patient. Quantitative evaluation parameters for PTV
indices are detailed in Table 2. Deviation parameters for
PTV indices had not been used as protocol deviation
parameter. The ICR-plan assessment was analyzed with the
same DR criteria. Feedback was provided to the investiga-
tors to either confirm that the plan was protocol compliant
or to recommend modifications if the plan was noncompli-
ant. Revised plans were further assessed and, if necessary,
additional changes were recommended. The QA deviations
were also assessed as to whether they may have an adverse
impact on tumor control or normal tissue toxicity.
Statistical method and considerations for correlation of
planning evaluation parameters
Spearman correlation (r) and Fischer exact tests were used
to determine the strength of the relationship between
continuous variables and to determine the strength of the
relationship between categorical variables, respectively.
We used the Kappa coefficient to compare the agreement
of the two reviewers. Statistical analyses were performed
with SAS 9.3 (SAS Institute, Inc., Cary, NC), p < 0.05 was
considered to be significant.
Results
Twelve EORTC institutions from 7 European countries
are currently participating in the EORTC 22042 study
and have jointly included 54 patients until May 20th,
2012. Seven percent (n=4) of the cases could not be
evaluated in QART review due to: non-submitted (n=2)
Table 1 Parameters for plan evaluation
PARAMETER Recommended Minor Deviation† Major Deviation†
Parameters for tumor control
Dose Prescription WHO grade II Simpson 1–3: 60 Gy - >60 Gy or <60 Gy
WHO grade III or Simpson 4–5: 70 Gy - <70 Gy or >70 Gy
Dose Conformity PTV D95% ≥ 95% of the prescribed dose PTV D95% = 90 – 94% of the
prescribed dose
PTV D95% < 90% of the prescribed dose
Target Volume Delineation PTV covers all CTV and GTV - GTV and CTV outside the PTV*
CTV covers all GTV - GTV outside the CTV
GTV to CTV margin 10 mm 11-15 mm >15 mm
Parameters for normal tissue toxicity
PTV D2% (Gy) <107% of the prescribed dose 107-110% of the prescribed dose >110% of the prescribed dose
Brainstem D2% or D0.5cc (surface) <64 Gy 64-65 Gy >65 Gy
Brainstem D2% or D0.5cc (center) <54 Gy 54–55 Gy >55 Gy
Optic Chiasm/Nerve D2% <60 Gy 60-61 Gy >61 Gy
Cochlea D2% <50 Gy 50-51 Gy >51 Gy
* PTV for dose evaluation may be restricted to 5 mm below the patient outer contour. † Cases with both major and minor deviations were considered as with major
deviation in overall analyses.
Abbreviations: PTV, Planning Treatment Volume; CTV, Clinical Target Volume; GTV, Gross Tumor Volume; D95%, D2%, Dose received by 95 and 2 percent of the volume,
respectively; D0.5cc, Dose received by 0.5 cc of the volume.
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were performed retrospectively due to corrupted or late
data submission. Five and 7 institutions were high- and
low-recruiters (≥ 5 vs. < 5 patients), submitting 74%
(n=37) and 26% (n=13) of the all accrued patients.Dummy run
The analysis of 12 DR-plans revealed 3 (25%) institutions
submitting plans with major deviations that did not
respect the requested RT dose of the trial: total dose for
PTV1 was limited to 54 Gy and/or the required dose
conformity for PTV1 was not protocol-compliant.
Contrast was omitted in 41% (n=5) of the DR-plans from
5 institutions without any mentioned medical contra-
indication. Eighty-three percent (n=10) of the centers
fulfilled the minimal dose constraints for the PTV
(D95 > 95%). Target volume delineation parameters and
maximum doses for the PTV and OAR were respected.
Mean values for the PTV1 RTOG Conformity index (CI),
Target Coverage (TC) and Homogeneity index (HI)
(Table 2) were 1.4 (0.5 - 2.4), 0.8 (0.3 – 1.0) and 0.1
(0.1 - 0.3), respectively.Table 2 Quantitative parameters measuring quality: definitio
Parameter [ref] Definition Optimal Va
RTOG Conformity Index (CI) [11] Vpi / VT 1.0
Target Coverage (TC) [12] VT,pi / VT 1.0
Homogeneity Index (HI)* [13] (D2%- D98%) / D50% 0.0
*HI minor and major deviations defined according to protocol deviation parameters fo
Abbreviations: Vpi, Prescription Isodose Volume; VT, Volume Target; VT,pi, 95% isodose
percent of the PTV, respectively.Individual case review
All plans from 12 institutions delivered RT for a total
dose of 60 Gy for PTV1 (n=50) and 70 Gy for PTV2
(n=7). Contrast was omitted in 24% (n=12) of the
ICR-plans from 7 institutions without any mentioned
medical contraindication. Fifty-six percent (n=28) of
all treatments was planned with IMRT, while 44%
(n=22) were planned with 3D-CRT. More than 4 fields
were used in a majority (77%; n=17) of the 3D-CRT plans.
Overall protocol deviations were observed similarly
whatever the treatment technique used (3D-CRT, 32%
deviation rate; IMRT, 32% deviation rate).
CTV/PTV dosimetry is summarized in Table 3. Mean
PTV CI, TC and HI (Table 2) were 1.5 (0.6 - 2.8), 1.0
(0.5 – 1.0) and 0.1 (0.0 - 0.4), respectively. At least one
major violation was observed in 18% (n=9) of the cases
according to parameters in Table 2. PTV indices were
found strongly inter-correlated (r=−0.41, p=0.0045 for
CI-HI; r=−0.81, p<0.0001 for TC-HI and r=0.70,
p<0.0001 for TC-CI). There was a negative correlation
between PTV volume and CI value (r=−0.50, p=0.0005).
Mean volumes of brainstem, pituitary, cochlea, optic
chiasm and optic nerve were 24.8±4.6, 0.4±0.2, 0.3±0.3,n of indices
lue Acceptable Minor Violation Major Violation
1.0 – 2.0 ≥ 0.9-1.0 or > 2.0-2.5 < 0.9 or >2.5
≥0.95 – 1.0 0.90 - 0.95 < 0.90
0.0 - 0.12 0.12 - 0.2 > 0.2
r dose conformity and PTV D2%.
volume within the target; D2%, D50%, D98%, Dose received by 2, 50 and 98
Table 3 Planning dose results for CTV and PTV in ICR-plans
Target Volume Mean Volume (cc), ±SD Mean D98% (Gy), ±SD Mean D95% (Gy), ±SD Mean D50% (Gy), ±SD Mean D2% (Gy), ±SD
CTV1 (n=50) 105.5 ±83.2 58.3 ±2.2 58.9 ±1.5 60.6 ±0.8 62.5 ±1.0
CTV2 (n=7) 67.0 ±83.9 67.7 ±3 68.6 ±1.8 70.9 ±0.7 72.9 ±1.6
PTV1 (n=50) 172.6 ±106.4 55.7 ±4.6 57.0 ±3.7 60.4 ±0.8 62.7 ±1.1
PTV2 (n=7) 99.2 ±97.3 65.8 ±4.5 67.8 ±2.4 70.9 ±0.6 73.1 ±1.4
Abbreviations: PTV, Planning Treatment Volume; CTV, Clinical Target Volume; D98%, D95%, D50%, D2%, Dose received by 98, 95, 50 and 2 percent of the
PTV, respectively.
Coskun et al. Radiation Oncology 2013, 8:23 Page 4 of 7
http://www.ro-journal.com/content/8/1/230.9 ±0.5 and 0.7±0.3 cc, respectively. The relationship
between CT slice thickness and OAR volumes showed
positive correlation for optic chiasm (r=0.55, p<0.0001)
and optic nerve (r=0.29, p=0.005) volumes. Mean values
of the maximum dose (D2%, Gy) for brainstem, pitui-
tary, cochlea and optic pathway were 16.0±2.0, 16.0 ±2.0,
10.0±15.0 and 18.0±2.0, respectively. Major deviations for
normal tissue toxicity were observed in ICR-plans inFigure 1 Observed deviations in EORTC 22042–26042 trial for Tumorwhich PTV consists of a part of the brainstem and/or
cochlea or optic nerve.
Deviations for tumor control and normal tissue
toxicity in ICR-plans are illustrated in Figure 1.
Major and minor deviations were observed in 22%
(n=11) and 10% (n=5) in all ICR plans. The observed
major deviations in this study had a potential impact
(i.e. would have had a critical impact on patient’sControl and Normal Tissue Toxicity.
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corrections) on tumor control (TCP) and normal
tissue complication probabilities (NTCP; Figure 1).
Among major deviations with a TCP impact, all but
one (2%) were related to dose conformity (Figure 1).
Regarding NTCP, major deviations were observed on
all OARs (Figure 1).
A good inter-observer agreement was observed, as the
two reviewers agreed in a majority (n=45; 90%) of
the cases after discussion (K=0.50; 95%CI: 0.14 - 0.86;
p=0.003). Fewer deviations were observed in plans
stemming from high recruiting institutions (≥5
patients), when compared to those stemming from
low recruiting centers (22% vs. 62%, respectively,
p=0.007). Although major deviations were tend to de-
crease by the subsequent years of accrual, we did not
observe an improvement in the protocol compliance
with time, as a result of the increase rate of minor
deviations (Figure 2).
No association between DR- and ICR-plan deviations
was observed (p=0.12). Eighty-nine percent (n=8/9) of
the institutions with no DR-deviation were found to
have subsequently deviations with ICRs. Likewise, 67%
(n=2/3) of institutions with DR-deviations did not have
later any ICR’s deviations.Figure 2 EORTC 22042–26042 Protocol-Compliance and -Deviations wDiscussion
To the best of our knowledge, the present study is the
first analysis of an interventional ICR QA procedure
prospectively performed in a clinical RT brain trial (i.e.
EORTC QA level 4 [2]). We have observed a substantial
number of deviations in approximately one third of
accrued patients that may have an impact on the
primary-end point (Figure 1). The impact of protocol
deviations on patient’s outcome [5], has been shown in a
number of prospective studies [6-8]. Interestingly, the
successful DR-plans did not guarantee protocol compli-
ance during subsequent ICR submissions and that the
overall deviation rate did not improve with time
(Figure 2). As such, ICR should be prospectively performed
in a clinical trial with RT.
Our report not only presents the data of this brain
trial but also gives us opportunity to challenge the
current QA paradigm. In previous studies, prospective
reviews could not be conducted or were considered as
ineffective [6,7,9]. We observed that only 7% of all ICRs
could not be analyzed in this trial. A substantial number
(18%) of cases were however retrospectively analyzed
due to late submission or corrupted files during first
submission to the digital QA platform. All (n=11) major
deviations and 80% (n=4) of the minor deviations wereith Time.
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cussed with institutions before the start of treatment. No
significant association (p=0.19) was observed between
the review type, prospective vs. retrospective, and the
deviation detection rate, but these data should be
cautiously interpreted due to the low number of patients
in the retrospective review arm (n=9).
There was a significant association (p=0.007) between the
number of accrued cases per institution and the number of
observed deviations. Peters et al. reported similar findings
in the prospective head and neck trial, with a cut-off of 5
patients per institution [8]. Duhmke et al. have also found
similar results for early stage Hodgkin lymphoma, with a
cut-off of 10 patients per institutions [10]. It would thus be
appropriate to limit the inclusion of patients into
prospective RT trials from reasonably high-accruing
institutions (i.e. 5 – 10 patients per institution), so as
to increase the protocol-compliance rate and possibly
improve patient’s outcome [5].
The DR is designed to identify systematic planning or
delivery RT errors and recognize protocol ambiguities
before study treatment starts. This procedure assures
that physicians understands the protocol requirement of
a given trial, delineate target volumes and OARs appro-
priately, produce a protocol-compliant plan and are able
to transfer the digital data to the QA platform [11].
Noteworthy, the DR deviation rate of 25% was observed
at the beginning of the trial and an overall deviation rate
of 32% was subsequently observed during patient’s
accrual. As such, the DR procedure did not improve the
protocol-compliance rate of the institutions, as no asso-
ciation between compliant- and non-compliant centers
with deviation rates was observed. Parenthetically, the
rate of i.v. contrast administration during RT planning
for DR and ICR improved however from 56% to 76%. A
DR-ICR correlation was observed in an EORTC prostate
trial, but not in a low-grade glioma brain (EORTC
22033–26033) trial [11]. Moreover, protocol compliance
did not improve within the trial accrual period (Figure 2).
Clinical trials usually take several years to be completed,
institutional physicists and physicians may change and
have a high turn-over rate, especially so for low-
recruiting institutions. This will consequently increase
the probability of protocol guidelines misinterpretation
and systemic planning errors. Due to the former issue,
QA analysis by the intergroup QA team should
always be performed by two reviewers and inter-rater
agreement should be reported. In our study there was
a significant association between the two reviewers
(K=0.5). Discrepancy was observed for only 5 ICR-plans
with minor deviations.
During our analysis, we computed CI and TC (Table 2)
to take into account both non-target tissue and PTV
[12,13]. HI was calculated for absorbed-dose distributionwithin the PTV according to ICRU 83 recommendations
[14]. There was a negative correlation between the PTV
volume and CI value for the ICR-plans (p=0.0005). Simi-
lar findings were previously reported by Musat et al. and
Knöos et al. [15,16]. We did not observe however any
association between CI value and tumor shape or OAR’s
vicinity or between PTV volume and TC or HI (p=0.10).
We recommend the prospective capture of the PTV
indices in clinical trials, as plan evaluation parameters,
for future survival/toxicity correlation analyses to define
optimal and suboptimal values (minor/major violations)
more accurately for the choice of ideal dosimetry.
In conclusion, we have observed a considerable number
of protocol deviations that may have a substantial impact
on tumor control or radiation-induced toxicity. In this
trial, DR could not avoid protocol non-compliance subse-
quently for ICR submission. Prospective ICR should be
conducted to prevent protocol deviations that may have
an impact on tumor control and/or toxicity. A substantial
number of ICRs could not be prospectively evaluated as
per protocol.
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